Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Refractory Angina in T2DM
NCT04143321Phase 4Completed
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in angina pectoris. Primary endpoint: Seattle Angina Questionnaire Physical Limitation at 6 weeks. Started Sep 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
angina pectoris
Beyond the preview
Go deeper on NCT04143321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143321.